Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to make preliminary assessment of PD-L1 and other immune related
biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with
recurrent glioblastoma